Compare OGS & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGS | ICUI |
|---|---|---|
| Founded | 1906 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.2B |
| IPO Year | N/A | 1992 |
| Metric | OGS | ICUI |
|---|---|---|
| Price | $76.81 | $146.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $84.57 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 504.3K | 255.7K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 11.73 | N/A |
| EPS | ★ 4.27 | N/A |
| Revenue | ★ $2,368,759,000.00 | $2,320,363,000.00 |
| Revenue This Year | $23.59 | N/A |
| Revenue Next Year | $4.35 | N/A |
| P/E Ratio | $18.14 | ★ N/A |
| Revenue Growth | ★ 15.06 | N/A |
| 52 Week Low | $66.38 | $107.00 |
| 52 Week High | $83.96 | $175.51 |
| Indicator | OGS | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 38.02 | 59.51 |
| Support Level | $76.55 | $145.32 |
| Resistance Level | $79.23 | $148.95 |
| Average True Range (ATR) | 1.46 | 4.01 |
| MACD | -0.11 | -0.63 |
| Stochastic Oscillator | 10.73 | 65.40 |
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.